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Abstract: Toxoplasma gondii (T. gondii) is a highly prevalent parasite that has no gold standard treatment due to the poor action or the numerous side effects. Focused sulfonamide-1,2,3-triazole hybrids
3a–c were wisely designed and synthesized via copper catalyzed 1,3-dipolar cycloaddition approach
between prop-2-yn-1-alcohol 1 and sulfa drug azides 2a–c. The newly synthesized click products were
fully characterized using different spectroscopic experiments and were loaded onto chitosan nanoparticles to form novel nanoformulations for further anti-Toxoplasma investigation. The current study
proved the anti-Toxoplasma effectiveness of all examined compounds in experimentally infected mice.
Relative to sulfadiazine, the synthesized sulfonamide-1,2,3-triazole (3c) nanoformulae demonstrated
the most promising result for toxoplasmosis treatment as it resulted in 100% survival, 100% parasite
reduction along with the remarkable histopathological improvement in all the studied organs.
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1. Introduction
Toxoplasma gondii (T. gondii) is a globally spread foodborne parasite that causes a
disease known as toxoplasmosis, infecting about 50% of the world’s population [1,2]. There
are three strains of T. gondii distributed according to their virulence. Type I strain (e.g., RH
strain) owes the highest virulence and is lethal at all doses, in all strains of mice, during the
acute proliferative stage of the disease [3–5]. The parasite has three main life cycle stages;
the rapidly multiplying tachyzoite (Greek tachos = speed), the encysted transmissible
stage found in tissues known as bradyzoite (Greek brady = slow) and the sexual stage
occurring in the feline intestine called oocyst [6,7]. T. gondii may infect the definitive
host by more than one pathway; ingestion of undercooked meat of an animal infected
with tissue cysts, ingestion of unclean vegetables contaminated with oocyst or it can be
transmitted during pregnancy from an infected mother to her fetus [2,8,9]. Toxoplasma
infection can be classified into acute or chronic stage according to the speed of infection.
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The acute stage occurs as a result of the rapidly proliferative tachyzoites where the cell
penetration requires the attachment between the conoid (anterior tip of tachyzoite) and the
host cell [2,3]. Tachyzoites can nearly invade all body tissues such as the liver, spleen, brain,
muscles, lung, eye and placenta [2]. Most infections are asymptomatic, although they might
be accompanied by fever, lymphadenopathy, muscular discomfort and headache [3]. On
the other hand, the disease is strongly associated with lethality in immunocompromised or
congenitally infected patients [2,3,8,9].
Despite the diversity of the currently available drugs for Toxoplasma, unfortunately,
most of them have poor effectiveness and are associated with many side effects, in addition
to their poor penetration to biological barriers such as the blood-brain barrier [2,10,11]. The
first line of therapy used to treat toxoplasmosis relies mainly on the inhibition of folate
synthesis pathway. Sulfadiazine is one of the sulfonamide groups acting on the folate
synthesis pathway which is essential for the parasite to form pyrimidine bases (cytosine,
thymine) in its DNA [12]. Sulfadiazine has relatively high tissue permeability; however, the
low water solubility may negatively affect its absorption [13,14]. Nitrogen-containing heterocyclic compounds, particularly 1,2,3-triazoles [15], have aroused the interest of medicinal
chemists in the creation of new therapeutic candidates due to its fascinating biomedical
applications and numerous pharmacological properties such as antibacterial [16], antiviral [17], antifungal [18], antimalarial [19], anti-HIV [20], antiallergic [21], antitubercular [22],
CNS depressant [23], analgesic [24], anticonvulsant [25], antihypertensive [26] and antiproliferative agents [27].
The molecular hybridization method, in which two or more distinct active pharmacophores are linked together with or without the use of a linker, is a simple way to discover
new drugs [28–30]. This method is currently the most frequently used in the development of new pharmacological scaffolds that target multiple sites [30]. As a result, hybrid
molecules can reduce the possibility of drug-drug interactions as well as multiple drug
resistance. Due to the extreme biological significance of the tunable 1,2,3-triazole core and
sulfonamide moieties, we disclose herein the development of some sulfonamide connected
1,2,3-triazole hybrids as a continuation of our interest in the development of such hybrid
molecules and the investigation of their synergetic effect [31–44].
Nanotechnology gained greater attentions after proving its efficacy in improving the
drugs’ pharmacokinetic profile. This includes enhancing the solubility, the dissolution
rate, the stability and above all modulating the drug permeability through absorption
into membranes leading to reduced drug doses [45]. One of the main goals of using
nanoformulations is related to their ability to enhance the penetration of the therapeutic
agents through biological barriers such as the blood–brain barrier (BBB) [46]. During
the past decades, chitosan has gained great attention and has been broadly applied in
pharmaceuticals development with respect to its excellent biological characteristics of
biocompatibility, absorptivity, non-hypersensitivity, biodegradability and wound healing
properties [47]. Numerous studies proved the effectiveness of chitosan nanoparticles as
anti-parasitic agent. Said et al. [48] reported the anti-Giardia lamblia effect of chitosan
nanoparticles. Another study showed the promising anti-Toxoplasma effect of chitosan
nanoparticles [49].
In the present study, the therapeutic efficacy of sulfonamide 1,2,3-triazole hybrids and
their novel nanoformulations were assessed in comparison to the gold standard sulfadiazine
in a murine model of acute virulent toxoplasmosis.
Rationale Study
Toxoplasmosis is deemed as one of the most serious diseases currently affecting
humans. Over the last decade, various investigations for disease prevention have been
envisioned against the tachyzoite form of T. gondii.
The modeling analysis revealed that pyrimethamine, which is found in the vast bulk of
medication regimens, is the most effective scaffold. However, the most effective treatment
molecular hybrids currently available are derived from pyrimethazine such as sulfadiazine,
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sulfamerazine, sulfamethazine and sulfapyrazine (Figure 1). These attractive scaffolds
prompted us to design and synthesize focused 1,2,3-triazole-sulfonamide molecular conjugates as mimic of corresponding features in the proposed scaffold, which will be used for
further investigation and evaluation of potential inhibition against T. gondii.

Figure 1. Schematic representation of the rational design.

2. Results and Discussion
2.1. Chemistry
Synthesis and Characterization
The strategy adopted for the synthesis of the focused sulfoamide-1,2,3-triazole hybrids
3a–c was depicted in Scheme 1. The most straightforward process for preparing 1,2,3triazoles-sulfoamide molecular hybrids is by using a direct and an efficient Cu(I)-catalyzed
azide-alkyne cycloaddition strategy (CuAAC), as documented in the literature [50]. By
adopting this approach, new 1,2,3-triazole-sulfoamide molecular conjugates 3a–c were
designed and synthesized through a copper-mediated 1,3-dipolar cycloaddition between
prop-2-yn-1-alcohol 2 as an alkyne and appropriate sulfa drug azides 1a–c as an organic
azide (Scheme 1), in the presence of copper sulfate and sodium ascorbate as catalysts.
It was noticeable that the used sulfa azides were obtained through the diazotization of
their selected sulfa drugs followed by their treatment with sodium azides according to the
reported literature [50].
The structures of the resulting 1,2,3-triazole-sulfonamide molecular conjugates 3a–c
were elucidated based on their spectral data. The spectral data of the click adduct 3a was
taken as the model to discuss the success of the click reaction. Thus, its IR clearly showed
the absence of the absorption bands of the alkyne groups (C≡C–H) and azides (N3 ) of its
corresponding starting materials 1 and 2a, and the presence of new absorption bands at
3487 cm−1 of the lateral hydroxyl group. On the other hand, the investigation of its 1 HNMR
data (Figure 2) confirmed the success of the click synthesis and exhibited the disappearance
of the acetylenic protons (≡C–H) of the propargyl side chain and appearance of the distinct
singlet at δH 8.79 ppm attributed to the H-5-triazolyl supporting the formation of triazole
ring of 3a. New signals were recorded at δH 8.53–7.07 ppm belonging to the aromatic
protons, 5.41 ppm assigning OH protons and δH 4.61 ppm attributed to the methylene
protons (CH2 ).
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Scheme 1. Synthesis of 1,2,3-triazole-sulfonamide molecular conjugates 3a–c.

Figure 2. 1 H NMR Spectrum of the 1,2,3-triazole-sulfoamide molecular conjugates 3a.
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Moreover, the 13 C NMR analysis (Figure 3) revealed the absence of the Sp-carbons
of the starting alkyne and presence of new aromatic and imine carbons between δC
158.95–120.27 ppm (See experimental section).

Figure 3.

13 C

NMR Spectrum of the 1,2,3-triazole-sulfoamide molecular conjugates 3a.

2.2. Formulation
Nanoparticles Characterization
The newly synthesized chitosan loaded 1,2,3-triazole-sulfoamide nanoparticles were
prepared through ionic gelation method. Data in Table 1 revealed that the loaded nanoparticles had a positive charge reflecting the stability of the prepared formulae that may be
attributed to the nature of the loaded compounds. The prepared nanoparticles had a
regular, smooth and spherical shape with average sizes of 76.3, 50.4 and 36.0 nm for NCs-3a,
NCs-3b and NCs-3c nanoparticles, respectively, as illustrated in Figure 4. The highest
entrapment and loading efficiencies were noticed with NCs-3c nanoparticles (89.27 and
43.31%, respectively) while NCs-3a and NCs-3b showed inferior results (Table 1).
Table 1. Particle size (PS), zeta potential (ζ potential), percentage of the entrapment efficiency (EE%),
percentage of loading efficiency (LE%) and polydispersity index (PDI) of the prepared nanoformulae.
Nano
Formulations

PS (nm)

ζ Potential (mV)

PDI

Entrapment
Efficiency % (EE%)

Loading
Efficiency (LE%)

NCs-3a
NCs-3b
NCs-3c

76.3 ± 10.9
50.4 ± 7.3
36.0 ± 10.4

+36.4 ± 2.7
+37.2 ± 0.8
+39.3 ± 1.9

0.34 ± 0.1
0.36 ± 0.03
0.35 ± 0.1

78.11 ± 1.70
80.15 ± 1.10
89.27 ± 1.23

38.42 ± 0.8
38.70 ± 0.5
43.31 ± 1.0
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Figure 4. TEM micrographs of NCs-3a (a), NCs-3b (b), NCs-3c (c) nanoparticles (100,000×) and
(d) calibration curve of the synthesized sulfonamide-1,2,3-triazole molecular conjugates.

2.3. Biological Assessment of the Novel Sulfonamide Derivatives
2.3.1. Clinical Behavior of Infected Mice
Infected untreated mice revealed a marked reduction in food intake with lethargic
attitude, hunched posture and ruffled fur on the fifth day post-infection. On contrary,
infected treated mice seemed comparatively healthy with good food intake. The uppermost
activity of mice was observed among subgroup IIf, receiving nanoparticles loaded with
the triazole-sulfonamidederivative 3c. These observations are in worthy agreement with
the previous studies [2,51].
2.3.2. Parasitological Study
Survival Time
In the present work, three crude triazole-sulfonamidederivatives 3a–c and their
nanoformulae were evaluated in addition to the commercially available sulfadiazine for the
treatment of mice infected with T. gondii virulent RH strain. Survival time was observed
for 30 days post-infection for all subgroups where a high significant difference in mice
survival was observed between treated and untreated subgroups (p < 0.001). The death
of infected untreated mice (subgroup Ia) started on the sixth day post-infection with no
survivors beyond the seventh day post-infection representing a mean survival time of
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6.6 days. Likewise, several studies reported the same finding. The rapid death of infected
mice may be clarified by the extensive spreading of the virulent Toxoplasma strain [2,51,52].
Difference in survival time of mice between the current work and other studies may be
attributed to different infection doses, type of strain used, route of infection, type of drug
used and mode of administration along with dose and duration of management [2,49,51].
All the treated mice revealed a significant increase in the mean survival time in comparison to the untreated control group; they indicated a mean ranging from 11.8 to 30 days. Subgroup IIf (mice treated with nanoparticles loaded with the triazole-sulfonamidederivative
3c) showed the longest survival time, whereas 100% of mice survived till the end of the
study exceeding the control subgroup Ib treated with sulfadiazine (Tables 2 and 3 and
Figure 5).
Table 2. Kaplan-Meier survival for all subgroups.
Subgroup

Mean Survival

% End of Study

Ia
Ib
IIa
IIb
IIc
IId
IIe
IIf

6.6
29.0
11.8
12.2
13.0
16.8
27.4
30.0

0.0
80.0
0.0
0.0
0.0
0.0
60.0
100.0

Log Rank
χ2

p

81.343 *

<0.001 *

*: Statistically significant at p ≤ 0.05.

Table 3. Log rank survival pairwise comparison between the different studied subgroups.
Subgroup

Ib

IIa

IIb

IIc

IId

IIe

IIf

Ia
Ib
IIa
IIb
IIc
IId
IIe

0.003 *

0.003 *
0.002 *

0.003 *
0.003 *
0.549

0.003 *
0.003 *
0.049 *
0.134

0.003 *
0.003 *
0.002 *
0.003 *
0.003 *

0.003 *
0.459
0.002 *
0.003 *
0.003 *
0.003 *

0.003 *
0.317
0.002 *
0.003 *
0.003 *
0.003 *
0.134

*: Statistically significant at p ≤ 0.05.

Figure 5. Kaplan-Meier survival curve for all subgroups.
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Parasite Load and Percent Reduction (%R)
A high statistically significant difference between all groups regarding parasite load in
the different studied organs was observed (AVOVA test, p < 0.001). The mean tachyzoites
count in the liver, spleen and brain of the infected untreated control was 10.74, 14.74 and
4.52/20 oil immersion field (OIF), respectively. Post hoc pairwise comparison showed
significant reduction in the parasite load between the infected untreated control and each
of the other treated subgroups. Similar observation was reported by Alves and Vitor [53]
who indicated the effectiveness of sulfadiazine in the treatment of toxoplasmosis [53].
Concerning the treated mice, the lowest mean tachyzoites count (highest percent reduction)
was observed among subgroup IIf, which successfully reached 100% reduction in parasite
load achieving better results than the control subgroup Ib treated with sulfadiazine (Table 4
and Figures 6 and 7). The observed reduction indicates successful tissue penetration and
blood–brain barrier passage of the used formula. This coincides with several studies
performed on drug-loaded NPs that ensured the tachyzoites reduction in different organs
compared to the unloaded drug [2,52,54]. The marked difference in the biological activity
between the sulfonamide analogues can be explained by the difference in the chemical
composition where 3a, 3b and 3c had azine, diazine and guanidine linked to substituted
1,2,3-triazole ring, respectively.
Table 4. Mean tachyzoites count and percent reduction in the liver, spleen and brain of the different
studied subgroups.

Liver
Mean
±SD.
F (p)
%
Reduction
Spleen
Mean
±SD.
F (p)
%
Reduction
Brain
Mean
±SD.
F (p)
%
Reduction

Subgroup
Ia (n = 5)

Subgroup
Ib (n = 5)

Subgroup
IIa (n = 5)

10.74
1.84

0.04 #
0.07

1.96 #
0.80

99.63

14.74
2.61

4.52
1.08

Subgroup
IIb (n = 5)

Subgroup
IIc (n = 5)

Subgroup
IId (n = 5)

Subgroup
IIe (n = 5)

Subgroup
IIf (n = 5)

1.72 #
1.17 #
0.54
0.69
56.471 * (<0.001 *)

1.07 #
1.84

0.66 #
0.81

0.0 #
0.0

81.75

83.99

89.11

90.04

93.85

100.0

0.04 #
0.09

2.32 #
0.49

2.01 #
1.56 #
2.38
0.70
41.833 * (<0.001 *)

1.45 #
3.16

0.04 #
0.09

0.0 #
0.0

99.73

84.26

86.36

89.42

90.16

99.73

100.0

0.0 #
0.0

0.80 #
0.67

0.81 #
0.61 #
0.83
0.65
30.448 * (<0.001 *)

0.26 #
0.44

0.12 #
0.22

0.0 #
0.0

100.0

82.30

82.08

94.25

97.35

100.0

86.50

Data were expressed using Mean ± SD. F: F for ANOVA test. Pairwise comparison between each 2 groups was
carried out using the post hoc test (Tukey). p: p value for comparing between the studied groups. *: Statistically
significant at p ≤ 0.05. # : Significant with subgroup Ia.
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Figure 6. Mean tachyzoites count in the liver, spleen and brain of the different studied subgroups.
#: Significant with subgroup Ia.

2.3.3. Morphological Study of Tachyzoites by Light Microscope and Scanning Electron
Microscope (SEM)
Peritoneal exudate of infected untreated mice was examined by light microscope
showing normal movement of tachyzoites with no signs of distortion. The tachyzoites of
subgroups IIa, IIb and IIc revealed slow movement, while sulfadiazine and NP-treated
tachyzoites showed complete loss of movement.
Examination of the peritoneal fluid of infected untreated mice using SEM revealed
normal tachyzoites that were elongate with entirely smooth surface. They had crescentshape possessing a rounded pole at one end and a pointed pole at the other with an obvious
conoid used in parasite penetration. Nevertheless, tachyzoites collected from all treated
subgroups presented loss in crescent shape, distortion of smooth surface, loss of tapered
ends and/or loss of the conoid. They also showed papules, lacerations, erosions and/or
ulcerations. The tachyzoite ultrastructural alterations were more apparent in subgroup IIf
where it appeared mutilated, ballooned and almost rupturing (Figure 8). These observed
changes were reported in other studies where the disorganized conoid was explained as an
apparent sign of the anti-Toxoplasma treatment efficiency. The positively charged chitosan
was reported to have the ability to form an electrostatic interaction with the negatively
charged membrane of tachyzoites resulting in their malformation along with the used
treatment [2,49,55].
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Figure 7. Giemsa-stained impression smears of liver, spleen and brain showing Toxoplasma tachyzoites
in infected untreated control and infected treated mice. (a): T. gondii tachyzoites in infected untreated
control liver (Giemsa stain ×1000). (b): T. gondii tachyzoites in infected treated liver (Giemsa
stain ×1000). (c): T. gondii tachyzoites in infected untreated control spleen (Giemsa stain ×1000).
(d): T. gondii tachyzoites in infected treated spleen (Giemsa stain ×1000). (e): T. gondii tachyzoites in
infected untreated control brain (Giemsa stain ×1000). (f): T. gondii tachyzoites in infected treated
brain (Giemsa stain ×1000).
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Figure 8. SEM of T. gondii tachyzoites collected from the peritoneal cavity of infected mice from
different studied subgroups. (a): Tachyzoite from subgroup Ia (infected untreated control), presenting
crescent shape with obvious conoid (×10,000). (b): Tachyzoite from subgroup Ib, showing evident
ballooning, distortion of the crescent shape with multiple large papules on the surface and loss of
the tapered ends. (×10,000). (c): Tachyzoite from subgroup IIa, showing loss in the crescent shape
with disorganized lacerated outer surface (×10,000). (d): Tachyzoite from subgroup IIb, showing
a shrunken distorted organism losing its crescent shape, tapered ends and conoid with marked
surface erosion and ulceration (×10,000). (e): Tachyzoite from subgroup IIc, showing mutilated
rapturing organism losing its conoid with disorganized lacerated surface (×10,000). (f): Tachyzoite
from subgroup IId, indicating lacerated parasite losing its smooth surface (×10,000). (g): Tachyzoite
from subgroup IIe, showing rapturing mutilated organism losing its conoid and smooth surface
(×10,000). (h): Tachyzoite from subgroup IIf, showing disfigured rapturing parasite with marked
ballooning along with damaged crescent shape and loss of the tapered ends (×10,000).

2.3.4. Histopathological Study
a. Liver: Microscopic examination of subgroup Ia liver sections showed disturbed
lobular architecture of the liver. Hepatic capsule was thickened and covered by tachyzoites
rich inflammatory exudate. The portal tracts showed moderate mononuclear inflammatory
infiltrate with evident interface hepatitis. The infiltrate was composed mainly of lymphocytes, plasma cells, histiocytes and rare eosinophiles. Evident congestion and dilatation
(ectasia) of central veins, portal vessels and sinusoids were frequently detected. Lobules
showed foci of lytic necrosis [>20/×10 high power field (HPF)], diffuse vacuolar degeneration and focal microvesicular steatosis. Centrilobular necrosis was also noted. Hepatocytes
showed intra- and extracellular high tachyzoites load (Figure 9a1–a3).
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Figure 9. Liver sections of different Toxoplasma-infected subgroups showed: (a) Subgroup Ia: (a1) loss
of normal lobular architecture of liver (100×). (a2) Moderate mononuclear portal inflammation
is seen as well as dilated ectactic portal vessels (P). Multiple foci of focal lytic necrosis are seen
(asterisk). They are seen as focal collection of lobular lymphocytes around apoptotic hepatocytes
(200×). (a3) Numerous tachyzoites (red arrows) intra- and extracellular within necrotic foci (400×).
(b) Subgroup Ib: (b1) Restoration of liver architecture (×100). (b2) Moderate portal inflammation
is still detected (P) and wide areas of vacuolar degenerative changes and microvesicular steatosis
(back arrows) (200×). (b3) Histologically free hepatocytes with occasional tachyzoites (red arrows).
(c) Subgroup IIa: (c1) Loss of normal lobular architecture (×100). (c2) Portal tracts (P) show mild
mononuclear inflammatory infiltrate and ectactic vascular spaces (200×). (c3) Necrotic hepatocytes
with evident residual tachyzoites (red arrows). (d) Subgroup IIb: (d1) Restoration of normal architecture of liver (×100). (d2) Mild portal inflammation is seen (P) with mild residual vascular
congestion/ectasia. Only one focus of focal lytic necrosis NPs detected (*) (200×). (d3) Normal histology with no tachyzoites detected in H&E staining (400×). (e) Subgroup IIc: (e1) Restoration of liver
architecture (×100). Mild portal inflammation is still detected (P). (e2) Few foci of focal lytic necrosis
are seen (*) (200×). (e3) Necrotic hepatocytes with evident residual few tachyzoites (red arrows)
(400×). (f) Subgroup IId: (f1) Low power view showing restoration of liver architecture (×100).
(f2) Mild portal inflammation is still detected (P) with improvement of vascular ectasia/congestion
and occasional foci of focal lytic necrosis is seen (asterisk) (200×). (f3) Histologically free hepatocytes.
No tachyzoites were detected (400×). (g) Subgroup IIe: (g1) Restoration of liver architecture (×100).
No portal inflammation (P) is still detected while mild vascular congestion is still seen. (g2) Few foci
of focal lytic necrosis are seen (asterisk) (200×). (g3) Necrotic hepatocytes with few rare residual
tachyzoites (red arrows) (400×). (h) Subgroup IIf: (h1) Restoration of liver architecture (×100). No
portal inflammation is still detected (P) or vascular congestion/ectasia. (h2) No focal lytic foci are
seen (200×). (h3) Histologically normal hepatocytes with no detected tachyzoites (400×).

Liver sections of subgroup Ib (infected and treated with sulfadiazine) revealed evident
reduction in portal inflammatory infiltrate with mild focal interface hepatitis. Vascular
congestion of portal vessels and central veins were still detected. Regarding hepatocytes,
focal lytic necrosis dropped to be 5/10 HPF while no centrilobular necrosis was seen. On
the other hand, grade III diffuse microvesicular steatosis was detected. Rarely, Toxoplasma
tachyzoites were seen (Figure 9b1–b3)). With regard to subgroup IIa (infected and treated
with 3a sulfadiazine analogue) minimal improvement of hepatic histology was observed
when compared to the control as focal lytic necrosis was still detected and counted up to
18/10 HPF. Portal inflammation, vascular inflammation and centrilobular necrosis were also
detected (Figure 9c1–c3)). Loading those drugs on chitosan nanoparticles (subgroup IId)
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improved its effect in toxoplasmosis treatment. The capsular inflammation was minimal
as well as portal inflammation with no interface hepatitis. Focal lytic necrosis foci were
7/10 HPF. No centrilobular necrosis or tachyzoites were detected (Figure 9d1–d3)). Mice of
subgroup IIb and IIc showed marked improvement of hepatic histology. Hepatocytes were
of normal morphology. They were arranged in cords and trabeculae showing eosinophilic
granular cytoplasm. No steatosis or necrosis were seen. Focal lytic necrosis dropped to
12/10 HPF and 5/10 HPF, respectively. No tachyzoites were detected by light microscopy.
Portal tracts showed minimal inflammation. Vascular congestion and dilatation were mild
and seen in a few tracts (Figure 9e1–e3) and Figure 9f1–f3)). Loading those drugs on
chitosan nanoparticles (subgroups IIe and IIf) increased their effect, as focal lytic necrosis
was only 4 and 2/10 HPF, respectively. Postal inflammation was decreased especially
in subgroup IIf (Figure 9g1–g3) and Figure 9h1–h3)). A similar finding was reported by
Allam et al., in 2021 when spiramycin-CS NPs showed nearly normal architecture with no
tachyzoites seen within the hepatocytes [56].
b. Spleen: Histopathological examination of spleen sections of the infected untreated
control (subgroup Ia) revealed disorganized architecture. The white pulp showed hyperplastic lymphoid follicles. They were of variable sizes with activated germinal centers in
most of them. Red pulp was widened with evident congestion and increased megakaryocytic count. Sinusoids were lined by hyperplastic littoral cells. Numerous non necrotizing
granulomas were seen formed of large epithelioid histiocytes loaded with tachyzoites.
Capsule was thickened and infiltrated by lymphocytes (Figure 10a1,a2).

Figure 10. Cont.

Int. J. Mol. Sci. 2022, 23, 4241

16 of 25

Figure 10. Histopathological spleen sections of different Toxoplasma-infected subgroups: (a) Subgroup
Ia: (a1) Regression of white pulp (W) and expanded congested red pulp (R) (100×). (a2) Red pulp
showing microgranulomas composed of scattered epithelioid histiocytes (red arrows) loaded with
intracytoplasmic tachyzoites (yellow arrows) (400×). (b) Subgroup Ib: (b1) Residual congestion of
red pulp (R) with slightly atrophic white pulp (W) (100×). (b2) Few histiocytes (red arrows) with
focally detected tachyzoites (yellow arrow) (400×). (c) Subgroup IIa: (c1) Minimal improvement.
Red pulp (R) is still congested on expanse of white pulp (W) (100×). (c2) Numerous epithelioid cells
(red arrows) with evident tachyzoites (yellow arrows) (400×). (d) Subgroup IIb: (d1) Expansion
of white pulp (W) and less red pulp congestion (R) (100×). (d2) Evident histiocytes (red arrows)
with rarely detected tachyzoites (yellow arrow) (400×). (e) Subgroup IIc: (e1) Expansion of white
pulp W) and less red pulp congestion (R) (100×). (e2) Few histiocytes (red arrows) with rarely
detected tachyzoites (yellow arrows) (400×). (f) Subgroup IId: (f1) Restoration of normal splenic
architecture with normal white pulp (W) and red pulp (R) (100×). (f2) Rare histiocytes (red arrows)
with no detected tachyzoites (400×). (g) Subgroup IIe: (g1) Improvement of white pulp (W) and less
congestion of red pulp (R) (100×). (g2) Rare histiocytes (red arrows) with few tachyzoites (yellow
arrows) (400×). (h) Subgroup IIf: (h1) Restoration of normal splenic architecture with normal white
pulp (W) and red pulp (R) (100×). (h2) Few histiocytes (red arrows) with no detected tachyzoites
(400×).
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Minimal improvement was seen in subgroup IIa (Figure 10c1,c2). Red bulb congestion and granulomas are still seen. Its effect was improved when the drug was
loaded on chitosan nanoparticles (subgroup IId) (Figure 10f1,f2). Moderate improvement was seen among subgroup IIb and subgroup IIc (Figure 10d1,d2,e1,e2) and their effect
was maximum when loaded on chitosan nanoparticles (subgroup IIe and subgroup IIf)
(Figure 10g1,g2,h1,h2). The effect of the treated subgroup subgroup IIf was comparable to
the commercially used sulfadiazine (Figure 10b1,b2). This result was in agreement with
El Temsahy et al. [52] who reported hyperplasia in lymphoid follicles with dilated congested sinusoids and multinucleated giant cells indicating a severe degree of inflammatory
changes secondary to infection with RH strain [52]. Lee et al. [57] reported that the spleen
is a very important organ that can be infected by tachyzoites of T. gondii, and parasitic
infiltration and apoptosis induction can occur even with a very low infection dose. This can
explain severe distortion in splenic architecture by infection [57]. Allam et al. [56] reported
persistence of extramedullary hematopoiesis in the spleen of infected mice with RH strain.
At the same time, the groups treated with spiramycin-CS NPs either in 400 mg/kg or 100
mg/kg revealed complete disappearance of necrosis and restoration of close to normal
architecture. There was regeneration of white pulp, well-structured lymphoid follicles with
reactive germinal centers and healthy demarcated red pulp [56].
c. Brain: Examination of subgroup Ia showed evident perivascular inflammatory
cuffing composed of mononuclear cells. Perivascular edema was also noted. Gliotic
nodules were seen as well as neuronal degenerative changes. Toxoplasmosis pseudocysts
were not detected by light microscopy. Mononuclear cuffing’s were not detected by light
microscopy in the studied cases. (Figure 11a). This was in agreement with a result reported
by El Temsahy et al. [52] where heavy inflammatory infiltrates were noticed in the cortex of
infected mice secondary to infection with RH strain [52]. With regard to the sulfadiazinetreated subgroup Ib, marked improvement was noted. Only few degenerated neurons were
seen but perivascular edema was still observed (Figure 11b). The subgroup treated with 3a
analogue showed no improvement of histologic changes as gliotic nodules and neuronal
degenerative changes were still noticed (Figure 11c). Both 3b and 3c treated subgroup
analogueanalogue-treated subgroups showed moderate improvement (Figure 11d,e) while
the nanoparticles formulation improved the effect of all the tested drugs, especially the
subgroup treated with 3c sulfadiazine (Figure 11f–h). No gliosis was detected and neuronal
degenerative changes were only rarely detected. The effect of all loaded drugs on chitosan
nanoparticles was similar to the commercially used sulfa. In agreement with this result
was that reported by Allam et al. [56] who noted an enhancement amelioration of the
encephalitis induced by the Toxoplasma infection after treatment with spiramycin-loaded
chitosan nanoparticles.
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Figure 11. Brain section of different Toxoplasma-infected models: (a) Subgroup Ia: Reveals multiple
foci of neuronal degenerative change (red arrows) and gliotic nodules (black arrow). Peri vascular
edema was seen (V). (b) Subgroup Ib: Marked improvement was noted. Only few degenerated
neurons were seen (red arrows) but perivascular edema is still seen (V). (c) Subgroup IIa: No
improvement was detected. Multiple foci of neuronal degenerative change were still noted (red
arrows) and gliotic nodule (black arrow). (d) Subgroup IIb: Marked improvement was noted. Only
few degenerated neurons were seen (red arrows). (e) Subgroup IIc: Moderate improvement was
noted. Some degenerated neurons were seen (red arrows). (f) Subgroup IId: Marked improvement
was noted. Only few degenerated neurons were seen (red arrows). (g) Subgroup IIe: Moderate
improvement was noted. Some degenerated neurons were seen (red arrows). Focal perivascular
edema is seen (V). (h) Subgroup IIf: Marked improvement was noted. Only few degenerated neurons
were seen (red arrows) (H&E, 200x).

3. Materials and Methods
3.1. Chemistry
Synthesis and Characterization of Sulfonamide-Based 1,2,3-Triazoles 3a–c
With stirring, a solution of copper sulfate (0.10 g) and sodium ascorbate (0.15 g) in
water (10 mL) was added to a solution of propargyl alcohol (1) (1 mmol) in DMSO (10 mL).
The appropriate sulfa azide 2a–c (1 mmol) was then added to the reaction mixture, which
was stirred at room temperature for 6–10 h. TLC (hexane-ethyl acetate) was used to monitor
the reaction, and after it was completed, iced water was added to the mixture. The resulting
precipitate was collected by filtration, washed with saturated ammonium chloride solution,
and recrystallized from ethanol/DMF to yield the desired 1,2,3-triazoles 3a–c.
Characterization of 4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-N-(pyrimidin-2-yl)
benzenesulfonamide (3a). It was obtained as white crystal in 88% yield; Mp: 185–186 ◦ C.
IR (KBr) ύmax /cm−1 : 1582 (C=C), 1639 (C=N), 2899, 2947 (Al.C-H), 3b6 (Ar.C-H), 33c(NH),
3487 cm−1 (OH). 1 H NMR (DMSO-d6 , 400 MHz): δH = 12.10 (1H, s, NHSO2 ), 8.79 (1H, s, CH1,2,3-triazole), 8.53 (2H, bs, Ar-H), 8.15 (4H, bs, Ph-H), 7.07 (1H, bs, Ar-H), 5.41 (1H, s, OH),
4.61 (2H, s, CH2 NH2 ). 13 C NMR (DMSO-d6 , 100 MHz): δC = 158.95, 158.85, 149.93, 144.56,
138.75, 127.99, 127.78, 121.65, 121.58, 120.42, 120.27 (C=N, Ar-C), 55.16 (CH2 ). Calculated
for C13 H12 N6 O3 S: C: 46.98; H: 3.64; N: 25.29. Found: C: 46.69; H: 3.35; N: 25.08. HRMS
(ESI): 332.0443 [M+ ].
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Characterization of 4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1-yl)-N-(pyridin-2-yl)
benzenesulfonamide (3b). It was obtained as yellow crystal in 86% yield; Mp: 223–224 ◦ C.
IR (KBr) ύmax /cm−1 : 1577 (C=C), 1642 (C=N), 2889, 2956 (Al.C-H), 3082 (Ar.C-H), 3323(NH),
3498 cm−1 (OH). 1 H NMR (DMSO-d6 , 400 MHz): δH = 12.58 (1H, s, NHSO2 ), 8.80 (1H,
s, CH-1,2,3-triazole), 8.13 (4H, bs, Ph-H), 6.87–7.20 (4H, m, Ar-H), 5.38 (1H, s, OH),
4.62 (2H, s, CH2 NH2 ). 13 C NMR (DMSO-d6 , 100 MHz): δC = 169.90, 163.73, 158.90, 157.86,
149.82, 147.99, 139.26, 132.93, 129.40, 128.47, 121.21, 120.12, 119.99 (C=N, Ar-C), 55.31 (CH2 ).
Calculated for C14 H13 N5 O3 S: C: 50.75; H: 3.95; N: 21.14. Found: C: 50.38; H: 3.55; N: 21.47.
HRMS (ESI): 331.0598 [M+ ].
Characterization of N-(diaminomethylene)-4-(4-(hydroxymethyl)-1H-1,2,3-triazol-1yl)benzenesulfonamide (3c). It was obtained as yellow pale crystal in 90% yield; Mp:
254–256 ◦ C. IR (KBr) ύmax /cm−1 : 1577 (C=C), 1642 (C=N), 2889, 2956 (Al.C-H), 3082 (Ar.CH), 3319–3376 (NH2 ), 3509 cm−1 (OH). 1 H NMR (DMSO-d6 , 400 MHz):δH = 8.78 (1H, s,
CH-1,2,3-triazole), 8.05 (2H, d, J = 4Hz, Ar-H), 7.93 (2H, d, J = 4 Hz, Ar-H), 6.90 (4H, s,
2xNH2 ), 5.45 (1H, s, OH), 4.62 (2H, s, CH2 ). 13 C NMR (DMSO-d6 , 100 MHz):δC = 158.31,
149.42, 144.22, 144.02, 138.58, 127.75, 121.87, 120.59, 119.99 (C=N, Ar-C), 55.54 (CH2 ). Calculated for C10 H12 N6 O3 S: C: 40.54; H: 4.08; N: 28.36. Found: C: 40.89; H: 4.37; N: 28.59.
HRMS (ESI): 296.0338 [M+ ].
3.2. Bioassay
3.2.1. Nanoparticles Preparation
0.5 g of chitosan (100–150 kDa, DDa ≈ 85%, Sigma-Aldrich, Saint Louis, MO, USA)
was dissolved in 100 mL of acetic acid solution (2% v/v) then stirred for 30 min and filtered
using Whatman filter paper no. 1. Sodium tri-poly phosphate (TPP) solution (0.2% w/v)
was prepared using deionized water then the 3a, 3b and 3c solutions (40 mg) were added
to the prepared TPP solution individually. Each mixture was then poured drop-wisely
to the prepared chitosan solution followed by continuous stirring for 30 min followed by
ultracentrifugation (25,000 rpm for 20 min). The resultant precipitate was stored at 4 ◦ C
in sterile falcon tubes for further investigations. All the chemicals were purchased from
Sigma-Aldrich (Saint Louis, MO, USA).
3.2.2. Characterization of the Nanoformulations
Dynamic light scattering technique was used to determine the particle size (PS),
polydispersity index (PDI) and ζ potential of the prepared nanoformulae by using Malvern
Zetasizer. Transmission electron microscopic (TEM) examination was used to detect the
ultra-structure, size and shape of the prepared nanoformulae [58]. Each nanoformulae
were lyophilized and weighed before further analyses.
3.2.3. Determination of the Loading and Entrapment Efficiencies
The loading and entrapment efficiencies of the prepared nanoformulae were assessed
by diluting each nanoformulae with phosphate-buffered solution (PBS) in a ration 1 to
10 v/v and then the diluted samples were centrifuged for 15 min at 15,000 rpm. UV/Vis
spectroscopy (Spekol 1300, Analytik Jena, Jena, Germany) was used to measure the percentage of the loaded and unentrapped drug in each supernatant separately with methanol
as a blank (at 280 nm) [58]. The percentage of the entrapment efficiency (EE%) was calculated according to Equation (1). While the percentage of the loading efficiency (LE%) was
calculated according to Equation (2)
EE% = Total initial drug − Total unentraped drug/Total initial drug × 100

(1)

LE% = Total entraped drug/Nanoparticles weight × 100

(2)
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3.3. Experminal Design and Animal Grouping
3.3.1. Parasite
T. gondii RH virulent strain was used in the present study. The strain was obtained
from the Parasitology Department, Faculty of Medicine, Alexandria University, Alexandria,
Egypt. The tachyzoites were maintained through their serial intraperitoneal passage into
Swiss albino mice. On the 4th day post-infection, the mice were sacrificed and their peritoneal fluid was washed three times with saline. Using a hemocytometer, the tachyzoites
number in the peritoneal exudate was adjusted to be utilized for infecting mice at a dose of
2500 tachyzoites/100 µL saline /mouse.
3.3.2. Drugs
In this study, the three newly synthetized sulfonamide-1,2,3-triazole hybrids 3a–c were
tested. Furthermore, the tested compounds were incorporated in chitosan nanoparticles
and their effects were also assessed. The effect of the blank chitosan nanoparticles on toxoplasmosis was previously assessed showing no absolute parasite reduction but improved
the efficacy of the loaded drug. All drugs were administered orally using the oral gavage
technique from day zero of infection for seven successive days. The dose per mouse was
dissolved in 100 µL saline for oral administration [2,59].
3.3.3. Grouping of Animals and Experimental Design
Eighty laboratory-bred male Swiss Albino mice were purchased from the animal
house of Pharos University in Alexandria, Egypt. Each mouse was 6–8 weeks old and
20–25 g at the start of the experiment. This animal study was approved by the Ethics
Committee of Alexandria University (0104837). Each mouse was infected with the RH
strain intraperitoneally in a dose of 2500 tachyzoites/100 µL.
Mice were divided into two main groups as follows:

•

Group I: Control group (20 mice):
It was subdivided into two subgroups:
- Subgroup Ia (10 mice): RH-infected untreated control [51].

Each mouse received 100 µL oral saline (the vehicle of the used drugs) by gavage
needle starting from the day zero of infection for seven successive days.
- Subgroup Ib (10 mice): RH-infected mice treated with sulfadiazine in a dose of
320 mg/kg/day for seven successive days [52].

•

Group II: Experimental group (60 mice):

It was subdivided into six treated subgroups (10 mice each). All synthetized sulfadiazine analogues were suspended in 100 µL saline/dose/mouse and were orally administered by gavage needle from the start of infection for seven days in a dose of
320 mg/kg/day.
- Subgroup IIa: RH-infected mice treated with 3a sulfadiazine analogue.
- Subgroup IIb: RH-infected mice treated with 3b sulfadiazine analogue.
- Subgroup IIc: RH-infected mice treated with 3c sulfadiazine analogue.
- Subgroup IId: RH-infected mice treated with nano-loaded 3a sulfadiazine analogue.
- Subgroup IIe: RH-infected mice treated with nano-loaded 3b sulfadiazine analogue.
- Subgroup IIf: RH-infected mice treated with nano-loaded 3c sulfadiazine analogue.

•

•

Five mice of each subgroup (either control or experimental) were observed daily for
early detection of abnormal feeding behavior. Survival time was recorded for thirty
days post-infection.
The other five mice were anesthetized and sacrificed by cervical dislocation on the 8th
day post-infection (24 h after the last dose of treatment). Liver, spleen and brain were
obtained from each mouse for further parasitological assessment. Peritoneal exudate
from each mouse was fixed in glutaraldehyde for further morphological studies using
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scanning electron microscope. Specimens from liver, spleen and brain tissues were
fixed in formalin for histopathological studies.
3.4. Evaluation of Drug Efficacy as Anti-Parasitic Agent
Assessment of each drug efficacy was carried out by clinical, parasitological and
morphological studies as follows:
3.4.1. Clinical Study
Mice were observed daily to identify any changes in the clinical behavior (attitude
and posture) and food intake [2,54].
3.4.2. Parasitological Study
Survival Rate
Five mice, from each studied subgroup, were observed daily to determine the percentage of mice living over time through Kaplan–Meier survival curve [2,60].
Parasite Load
Giemsa-stained impression smears of the liver, spleen and brain were prepared for
counting the tachyzoites. The mean count of tachyzoites of twenty different oil immersion fields from each organ of each mouse was then obtained (ten fields/each slide and
two slides/each organ). The tachyzoites mean number in each subgroup of mice was
estimated [2,55,61].
Percent Reduction (%R) in Parasite Load
The % R in the parasite load (mean tachyzoites count) in the liver, spleen and brain
was calculated according to the following equation [54]:
%R =

Mean count in infected untreated control group − Mean count in experimental group
× 100
Mean count in infected untreated control group
3.4.3. Morphological Study by Light Microscopy and Scanning Electron Microscopy (SEM)
The peritoneal fluid of all subgroups was collected on the sacrifice day and examined
by the light microscopy at 400× to demonstrate the effect of treatment on the movement of
T. gondii tachyzoites. The peritoneal fluid was then fixed in glutaraldehyde and prepared for
examining the ultra-structure of the parasites by SEM (JSM-IT 200, JOEL, Tokyo, Japan) [62].
3.4.4. Histopathological Study
The liver, spleen, and brain of each studied group were collected after the mice were
sacrificed. Different tissues were fixed in 10% formalin and processed into paraffin blocks.
Four microns sections were cut and mounted on glass slides for histopathologic assessment.
Hematoxylin and eosin (H&E) stain was used. Liver sections were assessed for architecture,
degree of portal inflammation (mild, moderate, and marked) and scored according to the
numbers of inflammatory foci (focal lytic necrosis) in ten 400xpower fields while searching
for Toxoplasma pseudocyst using light microscope [63]. Spleen sections were assessed for
architecture, changes in red and white pulp and presence/absence of tachyzoites. Brain
sections were also examined in different groups [64,65].
3.5. Statistical Analysis of the Data
Data were fed to the computer and analyzed using IBM SPSS software package version
20.0. (IBM Corp, Armonk, NY, USA). The Kolmogorov–Smirnov was used to verify the
normality of distribution of variables. ANOVA was used for comparing the studied groups
and followed by the post hoc test (Tukey) for pairwise comparison. Kaplan–Meier survival
curve was used for overall survival. Significance of the obtained results was judged at the
5% level [66,67].
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4. Conclusions
Novel sulfoamide-1,2,3-triazole molecular hybrids were successfully designed and
synthesized using Cu(I)-catalyzed 1,3-dipolar cycloaddition between propargyl amine and
appropriate sulfa drug azides. After full spectroscopic characterization, the newly synthesized 1,2,3-triazole-sulfa molecular conjugates were investigated for their Toxoplasma
efficiency. All synthesized sulfa derivatives 3a–c revealed a marked effectiveness in the
treatment of the virulent toxoplasma RH strain. The observed difference in the biological
activity between the sulfonamide analogues could be attributed to the difference in the
chemical composition where 3a, 3b and 3c had azine, diazine and guanidine linked to
substituted 1,2,3-triazole ring, respectively. Moreover, the study illustrated state-of-the-art
chitosan NPs used to convey the newer sulfonamide-1,2,3-triazole derivatives successfully to different tissues and bypass the blood–brain barrier. Remarkably, the synthesized
sulfonamide-1,2,3-triazole 3c nanoformula can be further considered as a potential candidate for toxoplasmosis treatment as it achieved 100% mice survival, 100% parasite reduction
as well as exhibiting a marked histopathological improvement in the examined organs.
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